Background: The mouse strain sparse fur with abnormal skin and hair (Spfash) is a model for the human ornithine transcarbamylase (OTC) deficiency, an
carries a single base-pair mutation in the OTC gene that leads to the production of OTC (4, 5) . The benefit of gene therapy in OTC-deficient mice has already been elaborated on biochemical and histochemical levels (6), however, it is not clear how efficiently the newly synthesized OTC precursor is translocated by the mitochondrial import mechanism and whether the secondary consequences of OTCD, such as depletion of ATPase (7, 8) and alteration of CPSI activity (9) (10) (11) Lee and Nussbaum (12) as described previously (6) .
Immunocytochemistry for Electron Microscopic Evaluation Liver tissues were fixed in 5% paraformaldehyde, 50 mM Hepes, pH 7 and cryoprotected with polyvinylpyrollidine/sucrose. The samples were then frozen in liquid nitrogen, sectioned (50 nm), and labeled using the technique of Tokuyasu (13, 14) . Thawed sections were incubated with the primary antibodies at room temperature for 45 min, followed by the secondary antibody for 45 min. The grids were then contrasted, embedded in 2% methylcellulose, and examined using a Philips 400 electron microscope. The primary antibodies used in this study were the following: a polyclonal rabbit antibody against hu-man OTC (15) The majority of hepatocytes in Spfash mice receiving Ad.mOTC (spfash/mOTC, 85.6 ± 11.6%) showed enlarged mitochondria, which were intensely labeled by the OTC antibody (Fig. 1) . Upon visual examination, the mitochondrial labeling density in spfash/mOTC ( Fig. 2A) OTC activity as measured using a cell lysate assay was 58.0 ± 7.5 ,umol citrulline/mg protein/hr in C3H control mice and 2.6 ± 0.1 in untreated Spfash mice (Fig. 3) larger a mitochondrion is, the smaller its surface density will be. The average value of mitochondrial surface density was 11.6 ± 3.6 lim-i in Spfash 10.9 ± 4.2 lum-1 in C3H control, 9.8 ± 2.9 ,im 1 in spfash/mOTC, and 12.3 ± 4.9 um 1 in Spfash/hOTC hepatocytes. As shown in Figure 5 , the mitochondrial surface density profile in spfash/mOTC hepatocytes shifted from that of untreated Spfash mice toward that of the normal C3H mice, whereas the mitochondrial surface density profile in SpfaSh/hOTC mice remained unshifted. (Fig. 7) . Quantitative evaluation showed that mitochondrial CPSI labeling density was 75.6 ± 44.9 gp/4m2 in untreated Spfash hepatocytes, 56.9 ± 32.9 gp/4im2 in control hepatocytes, 70.6 ± 40.8 gp/,im2 in spfash/mOTC, and 48.8 ± 38.8 gp/4Im2 in Spfash/ hOTC hepatocytes (Fig. 8) We further examined whether gene therapy was able to correct secondary alterations of OTC deficiency. It has been reported that CPSI activity is increased in spf mice (9, 10) and either normal (9) or decreased (11) in Spfash mice. In contrast to earlier reports, we found that mitochondrial CPSI concentration was significantly increased in untreated Spfash mice, which is consistent with the findings in spf mice (9) . The abnormally high levels of CPSI were partially corrected in mice treated with Ad.mOTC. Because CPSI is degraded with a half-life of 7.7 days (19), complete normalization of mitochondrial CPSI may be expected at a later time point following gene therapy. It was interesting that mitochondrial CPSI density was significantly reduced in Spfash/hOTC mice, while the cytosol and nuclear labeling density were significantly higher in these mice in comparison to those in untreated Spfash mice (Fig. 8) . We suggest that human OTC precursors may interfere with the mitochondrial import of CPSI precursor and therefore result in the reduced mitochondrial but increased cytosolic and nuclear concentration of the enzyme. liver following adenovirus-mediated gene transfer. This process is less efficient with human OTC expressed in mouse liver, presumably because of differences in amino acid sequence. The potential of adenovirus vectors in the treatment of urea cycle disorders is under evaluation in clinical trials (20) . 
